CD274 and non-small cell lung carcinoma: First, to our knowledge, this is the first study to assess the cost-effectiveness of pembrolizumab versus cemiplimab for the treatment of advanced NSCLC with high PD-L1 expression from a societal perspective using Markov and PS models.